Pharmaceutical compound
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.101.959  |
| (verify) | |
"Tetrachlorodecaoxide" (TCDO) is a chlorite-containing substance with claimed immunomodulatory, macrophage-activating properties. WF10 (Macrokine, Immunokine, Oxoferin) is an aqueous solution of tetrachlorodecaoxide designed for intravenous injection. Tetrachlorodecaoxide/WF10 were originally developed by Oxo Chemie. The chemical formula is given as Cl4H2O11. This incomplete formula shows a mixture of chlorite ion, water, and molecular oxygen: "Cl4H2O11" = 4ClO2 + H2O + O2. Oxoferin was found to be equivalent with aqueous sodium chlorite.
Tetrachlorodecaoxide / WF10 is used in the management of radiation cystitis, is effective in the treatment of diabetic foot ulcers, and is used in wound healing, where the mechanism of action is activation of the macrophage system, and increasing the partial pressure of oxygen in the wound.
References
- Maraprygsavan P, Mongkolsuk J, Arnhold J, Kuehne FW (June 2016). "The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome". Journal of Clinical & Translational Endocrinology. 4: 53–58. doi:10.1016/j.jcte.2016.05.001. PMC 5680448. PMID 29159131.
- ^ "WF10". Drugprofiles.informa.com. Retrieved 2016-12-20.
- "About Us". OXO Chemie (Thai). Archived from the original on 2016-12-20. Retrieved 2016-12-20.
- "Tetrachlorodecaoxide - Cl4H2O11-4". PubChem. U.S. National Library of Medicine. Retrieved 2016-12-20.
- Habermann E, Müller B (Jan 1989). "Oxoferin und Natriumchlorit — Ein Vergleich" [Oxoferin and sodium chlorite — a comparison]. Klinische Wochenschrift (in German). 67 (1): 20–25. doi:10.1007/bf01736530. PMID 2921839.
- Smit SG, Heyns CF (April 2010). "Management of radiation cystitis" (PDF). Nature Reviews. Urology. 7 (4): 206–14. doi:10.1038/nrurol.2010.23. hdl:10019.1/14211. PMID 20212517. S2CID 29208541.
- Yingsakmongkol N (March 2013). "Clinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers". Journal of Wound Care. 22 (3): 130–2, 134–6. doi:10.12968/jowc.2013.22.3.130. PMID 23665731.
- Parikh R, Bakhshi G, Naik M, Gaikwad B, Jadhav K, Tayade M (September 2016). "The Efficacy and Safety of Tetrachlorodecaoxide in Comparison with Super-oxidised Solution in Wound Healing". Archives of Plastic Surgery. 43 (5): 395–401. doi:10.5999/aps.2016.43.5.395. PMC 5040840. PMID 27689045.
External links
| Salts and covalent derivatives of the chlorite ion | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||